148 related articles for article (PubMed ID: 37301259)
61. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer.
Li D; Tan X; Yuan H; Yao X; Sun X; He L; Jiang L
Nucl Med Commun; 2023 Apr; 44(4):309-317. PubMed ID: 36756769
[TBL] [Abstract][Full Text] [Related]
62. Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma.
Choi WR; Oh JS; Roh JL; Kim JS; Oh I; Choi SH; Nam SY; Kim SY
Head Neck; 2019 Jun; 41(6):1846-1853. PubMed ID: 30675738
[TBL] [Abstract][Full Text] [Related]
63. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
64. Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
Kifjak D; Hochmair M; Sobotka D; Haug AR; Ambros R; Prayer F; Heidinger BH; Roehrich S; Milos RI; Wadsak W; Fuereder T; Krenbek D; Fazekas A; Meilinger M; Mayerhoefer ME; Langs G; Herold C; Prosch H; Beer L
Eur J Radiol; 2024 Jan; 170():111198. PubMed ID: 37992608
[TBL] [Abstract][Full Text] [Related]
65. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
66. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
67. Prognostic value of baseline
Xia L; Li X; Zhu J; Gao Z; Zhang J; Yang G; Wang Z
Radiat Oncol; 2023 Feb; 18(1):41. PubMed ID: 36829219
[TBL] [Abstract][Full Text] [Related]
68. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
69. Local and regional treatment response by
van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ
Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474
[TBL] [Abstract][Full Text] [Related]
70. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
71. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
72. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L
Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295
[TBL] [Abstract][Full Text] [Related]
73. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
74. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
[TBL] [Abstract][Full Text] [Related]
75. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
76. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.
Ryu IS; Kim JS; Roh JL; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):452-61. PubMed ID: 24081448
[TBL] [Abstract][Full Text] [Related]
77. Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.
Roh JL; Kim JS; Kang BC; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2014 Dec; 110(7):869-75. PubMed ID: 25088392
[TBL] [Abstract][Full Text] [Related]
78. FDG-PET metabolic tumor parameters for the reirradiation of recurrent head and neck cancer.
Velez MA; Veruttipong D; Wang PC; Abemayor E; St John M; TenNapel M; Chen AM
Laryngoscope; 2018 Oct; 128(10):2345-2350. PubMed ID: 29573279
[TBL] [Abstract][Full Text] [Related]
79. 18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
Feng Y; Wang P; Chen Y; Dai W
Nucl Med Commun; 2023 Oct; 44(10):900-909. PubMed ID: 37503694
[TBL] [Abstract][Full Text] [Related]
80. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
